HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Inoue, A. Articles by Kim, B. S. Search for Related Content PubMed PubMed Citation Articles by Inoue, A. Articles by Kim, B. S.

Suppressive Effect on Theiler’s Murine Encephalomyelitis Virus-Induced Demyelinating Disease by the Administration of Anti-IL-12 Antibody

Atsushi Inoue^*, Chang-Sung Koh^2,*, Masashi Yamazaki^*, Hiroyuki Yahikozawa^*, Motoki Ichikawa, Hideo Yagita and Byung S. Kim^§

^* Third Department of Medicine and Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan; Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan; and ^§ Departments of Microbiology-Immunology and Pathology, Northwestern University Medical School, Chicago, IL 60611

We examined the role of IL-12, a cytokine critical to the evolution of cellular responses, in the development of Theiler’s murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD). Treatment with mAbs to IL-12, especially during the effector phase, resulted in significant suppression of the development of this disease both clinically and histologically. In mice treated with these mAbs, the production of inflammatory and Th1-derived cytokines such as TNF- and IFN- in the spleen cells was decreased, and that of Th2-derived cytokines such as IL-4 and IL-10 was increased. The delayed type hypersensitivity and T cell proliferative response specific for TMEV were decreased by this treatment. These data suggest that IL-12 is critically involved in the pathogenesis of TMEV-IDD and that Abs to IL-12 could be a novel therapeutic approach in the clinical treatment of demyelinating diseases such as human multiple sclerosis.

This article has been cited by other articles:

				P. Kapil, R. Atkinson, C. Ramakrishna, D. J. Cua, C. C. Bergmann, and S. A. Stohlman Interleukin-12 (IL-12), but Not IL-23, Deficiency Ameliorates Viral Encephalitis without Affecting Viral Control J. Virol., June 15, 2009; 83(12): 5978 - 5986. [Abstract] [Full Text] [PDF]

				Y. Li, L. Fu, D. M. Gonzales, and E. Lavi Coronavirus Neurovirulence Correlates with the Ability of the Virus To Induce Proinflammatory Cytokine Signals from Astrocytes and Microglia J. Virol., April 1, 2004; 78(7): 3398 - 3406. [Abstract] [Full Text] [PDF]

				E. L. Oleszak, J. R. Chang, H. Friedman, C. D. Katsetos, and C. D. Platsoucas Theiler's Virus Infection: a Model for Multiple Sclerosis Clin. Microbiol. Rev., January 1, 2004; 17(1): 174 - 207. [Abstract] [Full Text] [PDF]

				M. Weeber, R. Vos, H. Klein, L. T.W. de Jong-van den Berg, A. R. Aronson, and G. Molema Generating Hypotheses by Discovering Implicit Associations in the Literature: A Case Report of a Search for New Potential Therapeutic Uses for Thalidomide J. Am. Med. Inform. Assoc., May 1, 2003; 10(3): 252 - 259. [Abstract] [Full Text] [PDF]

				J. P. Palma, R. L. Yauch, H.-K. Kang, H.-G. Lee, and B. S. Kim Preferential Induction of IL-10 in APC Correlates with a Switch from Th1 to Th2 Response Following Infection with a Low Pathogenic Variant of Theiler's Virus J. Immunol., April 15, 2002; 168(8): 4221 - 4230. [Abstract] [Full Text] [PDF]